NeuroSense Therapeutics

NRSN

Market cap $25.2M

Upgrade to unlock

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 100%

Negative

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

NeuroSense to Host Investor Webinar on December 8, 2025

Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass. , Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Host Investor Webinar on December 8, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass. , Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Provides Business Update and Progress for the First Half of 2025

CAMBRIDGE, Mass. , July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones & Go-to-Market Options in a Must-Watch Event CAMBRIDGE, Mass. , July 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Last Wednesday, NeuroSense Therapeutics Ltd. NRSN said it scaled up its production of PrimeC to a commercial scale.

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

See News Rankings